Acute pharmacologic blockade of dyskinesias in Parkinson's disease
β Scribed by Pierre J. Blanchet; Leo Verhagen Metman; M. Maral Mouradian; Thomas N. Chase
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 231 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Lerner and Bagic 1 have to be congratulated for their hypothesis on PD pathogenesis. They suggest that the sequence of the brain changes in PD follows specific and repeatable patterns in all cases, as well as that a prion-like process underlies neurodegeneration. These ideas could explain several fe
## Abstract Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson's disease patients were determined. Placeboβassociated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with id
Our objective was to develop parameters for objective ambulatory measurements of levodopa-induced dyskinesias (LID) in patients with Parkinson's disease (PD). Twentythree PD patients with mild to severe LID were submitted to a standardized protocol of 1-minute recordings during rest, talking, stress
Fluctuations in the symptoms of Parkinson's disease (PD), such as wearing-off and on-off effects, and dyskinesias are related to a variety of factors, including duration and dosage of levodopa, age at onset, stress, sleep, food intake, and other pharmacokinetic and pharmacodynamic mechanisms. The ma